Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
MLH1 negative Pembrolizumab penile cancer sensitive detail...
MSH6 negative Pembrolizumab penile cancer sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02426892 Phase II Nivolumab Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors Completed USA 0
NCT02721732 Phase II Pembrolizumab Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors Active, not recruiting USA 0
NCT02812056 Phase I Alisertib + Sapanisertib Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies Withdrawn 0
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT03260023 Phase Ib/II Avelumab Avelumab + Tipapkinogene sovacivec Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers Active, not recruiting USA | FRA | ESP 0
NCT03333616 Phase II Ipilimumab + Nivolumab Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Active, not recruiting USA 0
NCT03427411 Phase II Bintrafusp alfa Phase II Trial of M7824 in Subjects With HPV Positive Malignancies Completed USA 0
NCT03439085 Phase II Durvalumab + MEDI0457 Vaccine + Durvalumab in Human Papilloma Virus (HPV) Cancers Terminated USA 0
NCT03618953 Phase I Ad-E6E7 + Atezolizumab + MG1-E6E7 This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers (Kingfisher) Terminated USA | CAN 0
NCT03866382 Phase II Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors Recruiting USA 1
NCT04287868 Phase Ib/II Bintrafusp alfa + NHS-IL12 + PDS0101 Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies Active, not recruiting USA 0
NCT04432597 Phase Ib/II PRGN-2009 Bintrafusp alfa + PRGN-2009 HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers Active, not recruiting USA 0
NCT04491942 Phase I Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer Active, not recruiting USA | CAN 0
NCT04708470 Phase Ib/II Bintrafusp alfa + Entinostat + NHS-IL12 Entinostat + NHS-IL12 A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers Recruiting USA 0
NCT04902443 Phase I Nivolumab + Pomalidomide Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV Recruiting USA 0
NCT05526989 Phase II Dostarlimab-gxly + Niraparib Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma Recruiting USA 0
NCT06638931 Phase II Nivolumab Agnostic Therapy in Rare Solid Tumors (ANTARES) Recruiting BRA 0